673 related articles for article (PubMed ID: 19704173)
1. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir.
Boivin G; Goyette N; Rollag H; Jardine AG; Pescovitz MD; Asberg A; Ives J; Hartmann A; Humar A
Antivir Ther; 2009; 14(5):697-704. PubMed ID: 19704173
[TBL] [Abstract][Full Text] [Related]
2. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis.
Martin M; Goyette N; Ives J; Boivin G
J Clin Virol; 2010 Apr; 47(4):321-4. PubMed ID: 20138805
[TBL] [Abstract][Full Text] [Related]
3. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.
Boivin G; Goyette N; Gilbert C; Roberts N; Macey K; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Covington E
J Infect Dis; 2004 May; 189(9):1615-8. PubMed ID: 15116297
[TBL] [Abstract][Full Text] [Related]
4. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis.
Boivin G; Goyette N; Gilbert C; Covington E
J Med Virol; 2005 Nov; 77(3):425-9. PubMed ID: 16173018
[TBL] [Abstract][Full Text] [Related]
5. Molecular Analysis of Ganciclovir-Resistant Cytomegalovirus in Renal Transplant Recipients with High Viral Load.
Sohrabi M; Behzadian F; Hosseini SM; Lashini H
Arch Iran Med; 2016 Oct; 19(10):700-703. PubMed ID: 27743434
[TBL] [Abstract][Full Text] [Related]
6. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study.
Hantz S; Garnier-Geoffroy F; Mazeron MC; Garrigue I; Merville P; Mengelle C; Rostaing L; Saint Marcoux F; Essig M; Rerolle JP; Cotin S; Germi R; Pillet S; Lebranchu Y; Turlure P; Alain S;
J Antimicrob Chemother; 2010 Dec; 65(12):2628-40. PubMed ID: 20961907
[TBL] [Abstract][Full Text] [Related]
7. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus.
Allice T; Busca A; Locatelli F; Falda M; Pittaluga F; Ghisetti V
J Antimicrob Chemother; 2009 Mar; 63(3):600-8. PubMed ID: 19147520
[TBL] [Abstract][Full Text] [Related]
8. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients.
Marfori JE; Exner MM; Marousek GI; Chou S; Drew WL
J Clin Virol; 2007 Feb; 38(2):120-5. PubMed ID: 17157554
[TBL] [Abstract][Full Text] [Related]
9. High-dose Valganciclovir Treatment for Resistant Cytomegalovirus Colitis due to UL97 and UL54 Mutations.
Baradhi KM; Aure RL; El-Amm JM
Transplant Proc; 2018; 50(1):142-144. PubMed ID: 29407298
[TBL] [Abstract][Full Text] [Related]
10. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection.
Boutolleau D; Deback C; Bressollette-Bodin C; Varnous S; Dhedin N; Barrou B; Vernant JP; Gandjbakhch I; Imbert-Marcille BM; Agut H
Antiviral Res; 2009 Feb; 81(2):174-9. PubMed ID: 19063923
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients.
Boivin G; Goyette N; Gilbert C; Humar A; Covington E
Transpl Infect Dis; 2005; 7(3-4):166-70. PubMed ID: 16390409
[TBL] [Abstract][Full Text] [Related]
12. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis.
Boivin G; Gilbert C; Gaudreau A; Greenfield I; Sudlow R; Roberts NA
J Infect Dis; 2001 Dec; 184(12):1598-602. PubMed ID: 11740736
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of coexisting HCMV-UL97 and UL54 drug-resistance associated mutations in patients after haematopoietic cell transplantation.
Göhring K; Wolf D; Bethge W; Mikeler E; Faul C; Vogel W; Vöhringer MC; Jahn G; Hamprecht K
J Clin Virol; 2013 May; 57(1):43-9. PubMed ID: 23375740
[TBL] [Abstract][Full Text] [Related]
14. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
[TBL] [Abstract][Full Text] [Related]
15. Analysis of HHV-6 mutations in solid organ transplant recipients at the onset of cytomegalovirus disease and following treatment with intravenous ganciclovir or oral valganciclovir.
Bounaadja L; Piret J; Goyette N; Boivin G
J Clin Virol; 2013 Sep; 58(1):279-82. PubMed ID: 23871165
[TBL] [Abstract][Full Text] [Related]
16. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
Myhre HA; Haug Dorenberg D; Kristiansen KI; Rollag H; Leivestad T; Asberg A; Hartmann A
Transplantation; 2011 Jul; 92(2):217-23. PubMed ID: 21685829
[TBL] [Abstract][Full Text] [Related]
17. Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations.
Gracia-Ahufinger I; Gutiérrez-Aroca J; Cordero E; Vidal E; Cantisán S; del Castillo D; Martín-Gandul C; Rivero A; Torre-Cisneros J
Transplantation; 2013 Apr; 95(8):1015-20. PubMed ID: 23407543
[TBL] [Abstract][Full Text] [Related]
18. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients.
Humar A; Siegal D; Moussa G; Kumar D
J Infect Dis; 2005 Oct; 192(7):1154-7. PubMed ID: 16136456
[TBL] [Abstract][Full Text] [Related]
19. Ganciclovir-resistant post-transplant cytomegalovirus infection due to combined deletion mutation at codons 595-596 of the UL97 gene.
Leung PYM; Tran T; Testro A; Paizis K; Kwong J; Whitlam JB
Transpl Infect Dis; 2019 Dec; 21(6):e13168. PubMed ID: 31498954
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations.
Scott GM; Isaacs MA; Zeng F; Kesson AM; Rawlinson WD
J Med Virol; 2004 Sep; 74(1):85-93. PubMed ID: 15258973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
